Print Page | Sign In | Join Today
News & Press: Company News

CEL-SCI's RA Vaccine Selected by NIH

Thursday, November 5, 2015  
Share |
CEL-SCI Corporation’s LEAPS rheumatoid arthritis vaccine candidate has been accepted for a new program of technology commercialization and niche analysis managed by Foresight Science & Technology for the U.S. National Institutes of Health (NIH). CEL-SCI’s selection into this commercialization program, including market entry strategy and launch tactics, is an extension of the Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 awarded to CEL-SCI in July 2014 from the NIH’s National Institute of Arthritis Muscoskeletal and Skin Diseases (NIAMS).

“As we advance the clinical development program for our LEAPS rheumatoid arthritis vaccine, we are very pleased that the NIH has recognized the potential market value of this product. We believe the commercialization and program niche analysis will be of value to CEL-SCI as we apply for a Phase II SBIR grant to continue to support our efforts of bringing LEAPS into human clinical trials,” stated Daniel Zimmerman, Ph.D., Senior Vice President Research and Development, Cellular Immunology.

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected